Mark obtained his Master's degree in Pharmacogenetics from University College London (UCL). The company he established won the "Most Disruptive Start-up Award" from TechCity New (London's Technology City). Mark is devoted to advancing the application of AI genomic medicine to fundamentally improve patients' lives and revolutionize the healthcare industry. His research focuses on identifying clinical barriers to the adoption of genomic medicine, particularly its use in precision prescribing. In recent years, Mark has delivered a large digital health projects of the NHS.